Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging

Gait speed is an important measure of lower extremity physical performance in older adults and is predictive of disability and mortality. The biological pathways involved in the decline of lower extremity physical performance are not well understood. We used a targeted metabolomics approach to ident...

Full description

Saved in:
Bibliographic Details
Published in:The journals of gerontology. Series A, Biological sciences and medical sciences Vol. 74; no. 1; p. 62
Main Authors: Gonzalez-Freire, Marta, Moaddel, Ruin, Sun, Kai, Fabbri, Elisa, Zhang, Pingbo, Khadeer, Mohammed, Salem, Jr, Norman, Ferrucci, Luigi, Semba, Richard D
Format: Journal Article
Language:English
Published: United States 01.01.2019
Subjects:
Aged
Aging - physiology
Baltimore - epidemiology
Biomarkers - blood
Cross-Sectional Studies
Female
Follow-Up Studies
Gait - physiology
Geriatric Assessment - methods
Humans
Incidence
Lysophosphatidylcholines - blood
Male
Metabolomics - methods
Middle Aged
Mobility Limitation
Retrospective Studies
Sarcopenia - blood
Sarcopenia - epidemiology
Sarcopenia - physiopathology
Survival Rate - trends
Time Factors
Walking Speed - physiology
Baltimore
ISSN:1758-535X, 1758-535X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gait speed is an important measure of lower extremity physical performance in older adults and is predictive of disability and mortality. The biological pathways involved in the decline of lower extremity physical performance are not well understood. We used a targeted metabolomics approach to identify plasma metabolites predictive of change in gait speed over time. Gait speed was measured at baseline and over median follow-up of 50.5 months in 504 adults, aged ≥50 years, who had two or more study visits in the Baltimore Longitudinal Study of Aging (BLSA). Plasma metabolites were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates). Of 148 plasma metabolites (amino acids, biogenic amines, hexoses, glycerophospholipids) measured, eight were significantly associated with gait speed at baseline, independent of age and sex: hexoses (r = -0.148, p < .001), [sphingomyelin (SM) 16:1 (r = -0.091, p = .0009), SM 18:0 (r = -0.085, p = .002), SM 18:1 (r = -0.128, p < .0001], phosphatidylcholine aa 32:3 (r = -0.088, p = .001), lysophosphatidylcholine (LPC) 17:0 (r = 0.083, p = .003), LPC 18:1 (r = 0.089, p = .001), and LPC 18:2 (r = 0.104, p < .0001). Adjusting for baseline age, sex, and chronic diseases, baseline plasma LPC 18:2 was an independent predictor of the rate of change of gait speed over subsequent follow-up (p = .003). No other plasma metabolites were significantly associated longitudinal changes of gait speed over time. Low plasma LPC 18:2, which has previously been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment, is an independent predictor of decline in gait speed in older adults.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1758-535X
1758-535X
DOI:10.1093/gerona/gly100